Glucocorticoid availability in colonic inflammation of rat
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- 11-beta-hydroxysteroiddehydrogenasa typ 1 genetika metabolismus MeSH
- 11-beta-hydroxysteroiddehydrogenasa typ 2 genetika metabolismus MeSH
- antagonisté hormonů farmakologie MeSH
- budesonid farmakologie MeSH
- cyklooxygenasa 2 genetika metabolismus MeSH
- glukokortikoidy antagonisté a inhibitory metabolismus farmakologie MeSH
- interleukin-1beta genetika metabolismus MeSH
- karbenoxolon farmakologie MeSH
- kolitida chemicky indukované metabolismus MeSH
- kolon účinky léků enzymologie metabolismus MeSH
- kortikosteron metabolismus MeSH
- krysa rodu Rattus MeSH
- kyselina trinitrobenzensulfonová MeSH
- messenger RNA metabolismus MeSH
- mifepriston farmakologie MeSH
- modely nemocí na zvířatech MeSH
- mucin 2 MeSH
- muciny genetika metabolismus MeSH
- peroxidasa metabolismus MeSH
- polymerázová řetězová reakce s reverzní transkripcí MeSH
- potkani Wistar MeSH
- TNF-alfa genetika metabolismus MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- 11-beta-hydroxysteroiddehydrogenasa typ 1 MeSH
- 11-beta-hydroxysteroiddehydrogenasa typ 2 MeSH
- antagonisté hormonů MeSH
- budesonid MeSH
- cyklooxygenasa 2 MeSH
- glukokortikoidy MeSH
- interleukin-1beta MeSH
- karbenoxolon MeSH
- kortikosteron MeSH
- kyselina trinitrobenzensulfonová MeSH
- messenger RNA MeSH
- mifepriston MeSH
- Muc2 protein, rat MeSH Prohlížeč
- mucin 2 MeSH
- muciny MeSH
- peroxidasa MeSH
- Ptgs2 protein, rat MeSH Prohlížeč
- TNF-alfa MeSH
Recent in vitro studies have shown the involvement of pro-inflammatory cytokines in the regulation of the local metabolism of glucocorticoids via 11beta-hydroxysteroid dehydrogenase type 1 and type 2 (11HSD1 and 11HSD2). However, direct in vivo evidence for a relationship among the local metabolism of glucocorticoids, inflammation and steroid enzymes is still lacking. We have therefore examined the changes in the local metabolism of glucocorticoids during colonic inflammation induced by TNBS and the consequences of corticosterone metabolism inhibition by carbenoxolone on 11HSD1, 11HSD2, cyclooxygenase 2 (COX-2), mucin 2 (MUC-2), tumor necrosis factor alpha (TNF-alpha), and interleukin 1beta (IL-1beta). The metabolism of glucocorticoids was measured in tissue slices in vitro and their 11HSD1, 11HSD2, COX-2, MUC-2, TNF-alpha, and IL-1beta mRNA abundances by quantitative reverse transcription-polymerase chain reaction. Colitis produced an up-regulation of colonic 11HSD1 and down-regulation of 11HSD2 in a dose-dependent manner, and these changes resulted in a decreased capacity of the inflamed tissue to inactivate tissue corticosterone. Similarly, 11HSD1 transcript was increased in colonic intraepithelial lymphocytes of TNBS-treated rats. Topical intracolonic application of carbenoxolone stimulated 11HSD1 mRNA and partially inhibited 11HSD2 mRNA and tissue corticosterone inactivation and these changes were blocked by RU-486. The administration of budesonide mimicked the effect of carbenoxolone. In contrast to the local metabolism of glucocorticoids, carbenoxolone neither potentiates nor diminishes gene expression for COX-2, TNF-alpha, and IL-1beta, despite the fact that budesonide down-regulated all of them. These data indicate that inflammation is associated with the down-regulation of tissue glucocorticoid catabolism. However, these changes in the local metabolism of glucocorticoids do not modulate the expression of COX-2, TNF-alpha, and IL-1beta in inflamed tissue.
Zobrazit více v PubMed
J Invest Dermatol. 1982 Mar;78(3):206-9 PubMed
Life Sci. 1997;61(24):2391-6 PubMed
FEBS Lett. 2001 Nov 2;507(3):351-6 PubMed
J Clin Endocrinol Metab. 1999 Jan;84(1):291-9 PubMed
Dig Dis Sci. 2005 Dec;50(12):2366-78 PubMed
J Immunol. 2001 Jul 1;167(1):30-5 PubMed
Hum Reprod. 2002 Sep;17(9):2300-6 PubMed
Endocrinology. 2001 May;142(5):1982-9 PubMed
J Pharm Pharmacol. 1976 Feb;28(2):146-8 PubMed
Steroids. 2006 Mar;71(3):240-8 PubMed
Eur J Cell Biol. 2004 Aug;83(7):347-58 PubMed
Endocrinology. 2003 Dec;144(12):5568-77 PubMed
Gut. 1998 Dec;43(6):856-60 PubMed
Endocrinology. 1994 Dec;135(6):2533-41 PubMed
Endocr Rev. 1996 Feb;17(1):64-102 PubMed
Crit Care Med. 2004 Sep;32(9):1910-5 PubMed
Vitam Horm. 1999;57:249-324 PubMed
J Bone Miner Res. 2001 Jun;16(6):1037-44 PubMed
Dig Dis Sci. 2006 Feb;51(2):381-9 PubMed
Am J Respir Cell Mol Biol. 1999 Sep;21(3):403-8 PubMed
Endocr Rev. 2004 Oct;25(5):831-66 PubMed
J Pharmacol Exp Ther. 2001 Jun;297(3):1122-8 PubMed
Drug Metab Dispos. 1987 May-Jun;15(3):403-11 PubMed
J Exp Med. 1997 Jul 21;186(2):189-98 PubMed
Immunology. 1982 Apr;45(4):775-83 PubMed
J Interferon Cytokine Res. 2006 May;26(5):291-300 PubMed
Scand J Gastroenterol. 2004 Jun;39(6):549-53 PubMed
Biochim Biophys Acta. 2006 Apr;1765(2):189-222 PubMed
Mediators Inflamm. 1998;7(4):229-37 PubMed
Am J Respir Crit Care Med. 2003 May 1;167(9):1244-9 PubMed
Gastroenterology. 1989 Aug;97(2):326-37 PubMed
Gut. 1996 Feb;38(2):240-2 PubMed
J Endocrinol. 1996 Mar;148(3):561-6 PubMed
Gastroenterology. 1989 Mar;96(3):795-803 PubMed
J Steroid Biochem Mol Biol. 1999 Sep-Oct;70(4-6):203-10 PubMed
Biol Reprod. 1999 Jul;61(1):40-5 PubMed
J Immunol. 2005 Jan 15;174(2):879-89 PubMed
Biochem Pharmacol. 1997 May 15;53(10):1389-95 PubMed
Am J Physiol Gastrointest Liver Physiol. 2002 Jul;283(1):G187-95 PubMed
Dig Dis Sci. 1998 Nov;43(11):2518-25 PubMed
Physiol Res. 2004;53 Suppl 1:S63-80 PubMed
Tohoku J Exp Med. 2005 Dec;207(4):293-301 PubMed
Immunol Today. 1997 Sep;18(9):418-24 PubMed